摘要
目的:观察双丹明目胶囊对糖尿病大鼠模型视网膜血管内皮生长因子(VEGF)-a、VEGF-b、VEGF-c及其受体胎肝激酶-1(Flk-1)表达的影响。方法:将40只雄性SD大鼠,采用随机数字法分为正常组、模型组、双丹明目组、阳性对照组4组,每组10只20眼。除正常组外,其余3组大鼠采用STZ 50mg/kg的剂量一次性大鼠尾静脉注射法建立糖尿病性视网膜病变大鼠模型,造模后1周后开始连续灌胃用药,灌胃后8周,处死动物,免疫组化法检测视网膜组织中VEGF-a、VEGF-b、VEGF-c及其受体Flk-1的表达。结果成模后用药第8周,模型组、双丹明目组、阳性对照组视网膜中VEGF-a、VEGF-b、VEGF-c及其受体Flk-1蛋白表达平均光密度均高于正常组,其中模型组与正常组比较,差异有统计学性意义(P<0.01);双丹明目组、阳性对照组VEGF-a、VEGF-b、VEGF-c及其受体Flk-1表达的平均光密度值均低于模型组(P<0.01)。结论:双丹明目胶囊能明显降低VEGF-a、VEGF-b、VEGF-c及其受体Flk-1在糖尿病模型大鼠视网膜中的表达,对其视网膜有一定的保护作用。
Objective: To study the effects of Shuangdan Mingmu Capsule on the expressions of VEGF-a, VEGF-b,VEGF-c and its receptor Flk-1 in the retina in a diabetic rat model. Methods: Male SD rats(n=40) were divided into blank group(A),model group(B), Shuangdan Mingmu Capsule group(C) and positive control group(D) using the random number method(10 rats with 20 eyes per group). Except group A, rat model of diabetic retinopathy was established with the disposable injection of STZ(50 mg/kg) through rat tail vein in experimental rats in the other three groups. Intragastric administration was performed 1 week after the model was established, rats were sacrificed 8 weeks after intragastric administration, and the expressions of VEGF-a,VEGF-b, VEGF-c and its receptor Flk-1 in the retina tissues were detected by immunohistochemical method. Results: At the 8 th week of intragastric administration after modeling, lower average gray levels of the protein expressions of VEGF-a, VEGF-b,VEGF-c, and its receptor Flk-1 and higher average optical density were found in the model group, the Shuangdan Mingmu group and the positive control group compared with the blank group, additionally, there was a significantly difference between the model group and the blank group(P<0.01);higher average gray levels of the expressions of VEGF-a, VEGF-b, VEGF-c, and its receptor Flk-1 and lower average optical density were observed in the Shuangdan Mingmu group and the positive control group compared with the model group(P<0.01). Conclusion: Shuangdan Mingmu Capsule could significantly reduce the expressions of VEGF-a, VEGF-b, VEGF-c and its receptor Flk in the retina and had a certain protective effect on the retina of rats in the diabetic retinopathy model.
作者
彭俊
魏歆然
潘坤
刘峥嵘
秦裕辉
彭清华
PENG Jun;WEI Xin-ran;PAN Kun;LIU Zheng-rong;QIN Yu-hui;PENG Qing-hua(The First Hospital of Hunan University of Chinese Mdicine,Changsha 410007,China;Key Disciplines of TCM Ophthalmology,Hunan University of Chinese Medicine,Changsha 410208,China)
出处
《中华中医药杂志》
CAS
CSCD
北大核心
2019年第8期3447-3450,共4页
China Journal of Traditional Chinese Medicine and Pharmacy
基金
国家自然科学基金面上项目(No.81473737)
湖南省研究生科研创新项目(No.CX2016B377,No.CX2017B432)
中医药防治五官科疾病湖南省重点实验室建设项目(No.2017TP1018)
长沙市科技计划项目(No.kc1704005)
中央财政支持地方高校建设项目
湖南中医药大学中医学国内一流建设学科
国家中医药管理局中医眼科学重点学科建设项目
湖南省中医五官科学重点学科建设项目~~
关键词
双丹明目胶囊
糖尿病性视网膜病变
VEGF-A
VEGF-B
VEGF-C
FLK-1
Shuangdan Mingmu Capsule
Diabetic retinopathy
Vascular endothelial growth factor-a(VEGF-a)
Vascular endothelial growth factor-b(VEGF-b)
Vascular endothelial growth factor-c(VEGF-c)
Fetal liver kinase 1(Flk-1)